Hisven 16 Tablet contains Betahistine 16 mg as its active ingredient, primarily indicated for the treatment of vertigo associated with Ménière’s disease and other vestibular disorders. Betahistine acts as a histamine analog, exerting its therapeutic effect by improving microcirculation in the inner ear, thereby reducing endolymphatic pressure and alleviating symptoms such as dizziness, tinnitus, and hearing loss. The drug functions as a partial histamine H1 receptor agonist and a strong H3 receptor antagonist, which enhances histamine release and improves vestibular compensation. Hisven 16 is typically administered orally, with dosage tailored according to the severity of symptoms and patient response. Commonly, it is prescribed at 16 mg two to three times daily. The medication is generally well tolerated; however, some patients may experience mild gastrointestinal disturbances or headache. Betahistine is contraindicated in patients with pheochromocytoma and should be used cautiously in individuals with a history of peptic ulcers or asthma. It is essential to follow the prescribed dosage regimen and consult a healthcare professional before initiating therapy. Hisven 16 Tablet offers an effective option for managing vestibular dysfunctions, improving patient quality of life by mitigating vertigo and associated symptoms.